IGWM
RNTX

ICA Group Wealth Management’s Rein Therapeutics RNTX Stock Holding History

ICA Group Wealth Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$663 – 1361
2024
Q1 		$663 Hold
100
– – ﹤0.01% 1273
2023
Q4 		$305 Buy
+100
New +$195 ﹤0.01% 1304
2023
Q3 		– Sell
-100
Closed -$179 – 1287
2023
Q2 		$179 Hold
100
– – ﹤0.01% 1298
2023
Q1 		$124 Buy
+100
New +$214 ﹤0.01% 1253

Other funds holding RNTX

UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

ICA Group Wealth Management's RNTX Position: Q2 2024 in Review

ICA Group Wealth Management sold out of Rein Therapeutics (RNTX) in Q2 2024, closing a stake of 100 shares — an estimated $663 sold.

ICA Group Wealth Management first reported a position in RNTX in Q1 2023 and held it in 4 quarters. The position peaked at $663 in Q1 2024. 29 funds tracked by Wall St. Rank hold RNTX as of Q2 2024.

  • ICA Group Wealth Management reported no remaining Rein Therapeutics position as of Q2 2024 after selling out during the quarter.
  • ICA Group Wealth Management sold 100 Rein Therapeutics shares in Q2 2024, an estimated $663.
  • ICA Group Wealth Management first reported a position in Rein Therapeutics in Q1 2023 and held it in 4 quarters.
  • ICA Group Wealth Management's Rein Therapeutics position peaked at $663 in Q1 2024.
  • 29 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2024.

Based on ICA Group Wealth Management's 13F filing for Q2 2024, filed 8 Aug 2024.